Special Issue

Psychedelic and Interventional Psychiatry

Message from the Guest Editor

Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and a significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating the rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. This Special Issue encourage contributions that focus on the following areas:

LSD in generalized anxiety disorder and depression; Psilocybin in treatment-resistant depression (TRD), anorexia nervosa and other eating disorders, and alcohol use disorders;

Ketamine (and Esketamine): PTSD, depression, and suicidal ideation;

Nitrous oxide in TRD;

MDMA in PTSD;

Deep-brain stimulation (DBS), Transcranial magnetic stimulation (TMS): non-invasive and FDA-approved for depression, anxiety, OCD, and PTSD;

Ibogaine: studied for opioid dependence and TBI; DMT (Dimethyltryptamine): applications in end-of-life anxiety, TRD, and other mood disorders;

Other psychedelic interventions.

Guest Editor

Dr. Mark S. Gold Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA

Deadline for manuscript submissions

30 April 2026



Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.6 Indexed in PubMed



mdpi.com/si/223016

Brain Sciences Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 brainsci@mdpi.com

mdpi.com/journal/ brainsci





Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.6 Indexed in PubMed



brainsci



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.